MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion

    R. Serpa, K. Palsa, E. Tufano, T. Helmuth, S. Mills-Huffnagle, M. Kant, J. Connor (Hershey, USA)

    Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…
  • 2025 International Congress

    Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

    M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

    Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
  • 2025 International Congress

    European Experience with Long-term Continuous Subcutaneous Apomorphine Infusions at Higher Doses

    M. Grall, J. Parsons, A. de Groot, A. Sesar, P. Qin, M. Vérin (Rockville, USA)

    Objective: Outline European Union (EU) long-term experience with higher doses (≥6 mg/h or ≥100 mg/d) of continuous subcutaneous apomorphine infusion (CSAI). Background: The EU TOLEDO…
  • 2025 International Congress

    Risk factors for central nervous system side effects of amantadine

    M. Nagai, N. Miyaue, Y. Ito, Y. Yamanishi, R. Ando, Y. Ihara (Ehime, Japan)

    Objective: The purpose of this study was to investigate the threshold blood level of amantadine and risk factors for central nervous system (CNS) side effects…
  • 2025 International Congress

    Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures

    N. Elayan, L. Rubin, M. Mccrossin, C. Roberts, H. Shakil, A. Di Rocco, M. Ghilardi (Long Island, USA)

    Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…
  • 2025 International Congress

    Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease

    A. López Lobato, D. Náfate Wences, A. Hernández Medrano, A. Cervantes Arriaga, M. Rodriguez Violante (Mexico, Mexico)

    Objective: To evaluate the association between Cannabidiol (CBD) usage and cognitive performance, measured by The Montreal Cognitive Assessment (MoCA) in people living with Parkinson's Disease…
  • 2025 International Congress

    Isolation of Seeding Competent Material by Means of ThT Extraction

    C. Farris, Y. Ma, D. Murphy, S. Rosete-Gonzalez, L. Concha (san diego, USA)

    Objective: To develop a method for capturing α-synuclein (syn) seeds from cerebrospinal fluid (CSF) and other matrices with high affinity by means of thioflavin T…
  • 2025 International Congress

    Monitoring Parkinson’s Disease in the Dental Chair

    J. Schwartz, L. Dibenedetto, P. Engen, V. Ha, B. Killinger, C. Soto, S. Green, A. Naqvi, S. Tomar, M. Shaikh, M. Villanueva, D. Sanchez-Bass, C. Noh, R. Voigt, C. Goetz, A. Keshavarzian (Chicago, USA)

    Objective: Our goal is to bridge the mechanistic knowledge gap on the Microbiota-Gut-Oral-Brain-Axis (MGOBA)’s role in Parkinson’s disease (PD) pathogenesis through a case-control, proof-of-concept, observational…
  • 2025 International Congress

    Clinical Characteristics of Sporadic Parkinson’s Disease with Negative CSF Alpha-synuclein Seed Amplification Assay

    S. Brooker, J. Pasquini, S. Choi, D. Lafontant, K. Marek, T. Simuni, P. Gonzalez-Latapi, N. Pavese, K. Poston (Chicago, USA)

    Objective: Define clinical characteristics of individuals with sporadic Parkinson’s disease (sPD) enrolled in the Parkinson’s Progression Markers Initiative (PPMI) who have a negative CSF alpha-synuclein…
  • 2025 International Congress

    Three Biopsies Optimizes Test Performance for the Detection of Cutaneous Phosphorylated Alpha-Synuclein

    T. Levine, B. Bellaire, H. Khona, R. Freeman, C. Gibbons (scottsdale, USA)

    Objective: To review two independent data sets to define the test performance of skin biopsies for the detection of P-SYN and peripheral nerve degeneration in…
  • « Previous Page
  • 1
  • …
  • 129
  • 130
  • 131
  • 132
  • 133
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley